A fresh oral medication for baldness delivered encouraging outcomes during a late-stage trial, boosting hair restoration in men following a six-month period.
Veradermics, a US pharmaceutical company, reported that its test pill named VDPHL01 surpassed a placebo in an evaluation featuring over 500 male participants experiencing mild to moderate male pattern hair loss.
According to the firm, the study achieved all primary and secondary objectives, displaying steady hair growth enhancements across subjects. Participants tolerated the therapy well overall, and investigators noted no severe adverse reactions tied to the drug.
The medication VDPHL01 features a customized formulation of minoxidil designed to dispense the drug gradually. Minoxidil currently sees widespread use as a topical scalp application for male and female hair loss.
Prakhar Agrawal, an analyst with Cantor Fitzgerald, stated that the favorable study outcomes boost the commercial viability of the Veradermics product, even though lower-cost generic oral minoxidil alternatives exist.
Nutrafol, a Unilever-supported hair growth supplement, was named by the business as a potential pricing guide for the new pill. Nutrafol carries a price tag of near $90 monthly, equating to roughly $1,000 every year.
Further findings from a separate section of the research are scheduled for release by the organization later in the year.
Additional drug manufacturers, such as Pelage Pharmaceuticals and Cosmo Pharmaceuticals, are working on competing hair loss therapies.
